



2024

INDEPENDENT COMMUNITY PHARMACY LEGISLATIVE PRIORITIES

*Important pro-pharmacy, pro-patient, and pro-taxpayer legislative measures are advancing through regular order in both the House and Senate with overwhelming bipartisan support. **Congress must swiftly finalize and pass PBM reform legislation that contains the following:***

- The *Drug Price Transparency in Medicaid Act* (H.R. 1613/S. 1038), sponsored by Reps. Buddy Carter (R-Ga.) and Vicente Gonzalez (D-Texas) in the House and Sens. Peter Welch (D-Vt.) and Roger Marshall (R-Kan.) in the Senate. It prohibits the use of spread pricing in Medicaid managed care programs and would move to a fair and transparent pharmacy reimbursement system based on average acquisition costs plus the state's Medicaid fee-for-service dispensing fee. It requires all pharmacies to respond to the National Average Drug Acquisition Costs (NADAC) survey. **This legislation also saves taxpayers over \$1 billion.**
 - **Passed the full House by a vote of 320-71** as part of the *Lower Costs, More Transparency Act* (H.R. 5378)
 - Included in the *Modernizing and Ensuring PBM Accountability Act* (S. 2973), which **passed the Senate Finance Committee 26-1**

- The *Neighborhood Options for Patients Buying Medicines (NO PBMs) Act* (H.R. 5400/S. 2436), introduced by Reps. Buddy Carter (R-Ga.) and Debbie Dingell (D-Mich.) in the House and Sens. Joe Manchin (D-W.Va.) and Marsha Blackburn (R-Tenn.) in the Senate. It requires CMS to define and enforce "reasonable and relevant" Medicare Part D contract terms. It also would create a process for pharmacies to report contract violations and give the Centers for Medicare & Medicaid Services tools to oversee and enforce reasonable and relevant contract requirements.
 - **Unanimously passed Senate Finance Committee** as part of the *Better Mental Health Care, Lower-Cost Drugs, and Extenders Act* (S. 3430)